Physician profile
Brian K Wise
NPI 1043211683
$43,877.63
in general payments reported to CMS, 2019-2025
10 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,227 · 2021: $26K · 2022: $299 · 2023: $46.35 · 2024: $167 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23,929.71 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $9,015.95 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $5,223.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $3,441.70 | 2019-2021 | |
| Abbvie INC. | $1,989.99 | 2021-2024 | |
| Alkermes, INC. | $201.50 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.06 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.28 | 2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $17.70 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.08 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.